Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial-Reference-Cited by-同舟云学术

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

Published:2020-09 Issue:9 Volume:7 Page:e660-e670
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Diefenbach Catherine S,Hong Fangxin,Ambinder Richard F,Cohen Jonathon B,Robertson Michael J,David Kevin A,Advani Ranjana H,Fenske Timothy S,Barta Stefan K,Palmisiano Neil D,Svoboda Jakub,Morgan David S,Karmali Reem,Sharon Elad,Streicher Howard,Kahl Brad S,Ansell Stephen M

Publisher

Elsevier BV

Subject

Hematology

Reference30 articles.

1. Lymphoma in adolescents and young adults;Brugieres;Prog Tumor Res,2016

2. Hodgkin lymphoma: diagnosis and treatment;Ansell;Mayo Clin Proc,2015

3. Targeting immune checkpoints in lymphoma;Ansell;Curr Opin Hematol,2015

4. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma?;Khan;Exp Hematol,2006

5. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape;Aldinucci;J Pathol,2010

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma;JCO Oncology Practice;2024-09-12

2. Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-09-06

3. The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review;Pediatric pharmacology;2024-07-03

4. Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma;Cancer Research Communications;2024-07-01

5. Immune‐related adverse events of antibody‐based biological medicines in cancer therapy;Journal of Cellular and Molecular Medicine;2024-07